logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru.

Chronopharmacology of lithium preparations

[Review]
Eduard Arushanyan;

As shown by modern literature data, the time factor plays an important role in the pharmacodynamics of lithium used for the treatment of bipolar affective disorder (BAD). Its chronotropic properties may depend on the effect on the function of suprachiasmatic nuclei of the hypothalamus, as well as inhibition of glycogen synthase-3 kinase and the mobilization of the epiphyseal hormone melatonin.

Download

References:
1. Arushanian E. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 1996;46:16-22.
2. Arushanian E. B. Med. Vestn. Sev. Kavkasa. – Med. News of North Caucasus. 2007;6:3-16.
3. Arushanian E. B. Unicalny melatonin. Stavropol, 2007.
4. Arushanian E. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 2011;61:645-659.
5. Arushanian E. B. Hronopatologia i hronomedizina. – Chronopathol. and chronomed. 2012:122-140.
6. Arushanian E. B. Eksper. I clin. Pharmacol. – Exper. Clin. Pharmacol. 2012;75:44-49.
7. Arushanian E. B., Ovanesov K. B. Jurn. Vysh. Nerv. Dejat. – J. High Nerv. Activ. 1991;41:822-827.
8. Markova N. A., Shvezova E. F. Patogenes. – Pathogenesis. 2013;11:4-8.
9. Abe M., Herzog E. D., Block G. S. Neurorport. 2000;11:3261-3264.
10. Abreu T., Braganca M. J. Affect. Disord. 2015;185:219-229.
11. Anderson G., Maes M. Pharm. Res. 2014;20:3812-3847.
12. Bellivier F., Geoffroy P. A., Etan B. Expert. Opin. Ther. Targets. 2015;19:747-763.
13. Besing R. C., Paul J. R., Habitz L. M. [et al.] J. Biol. Rhythms. 2015;30:155-160.
14. Crofton E. J., Nenov M. N., Zhang Y. Neuropharmacology. 2017;117:49-60.
15. Etan B., Dumaine A., Bellivier F. Hum. Mol. Genet. 2012;21:4030-4037.
16. Fomaro M., McCarthy M. J., De Berardis D. Neuropsychiatry Dis. Treat. 2013;9:243-251.
17. Geoffroy P. A., Curis E., Courtin C. World J. Biol. Psychiatry. 2017;16:1-31.
18. Geoffroy P. A., Etan B., Franchi J. A. Curr. Pharm. Des. 2015;21:3352-3358.
19. Geoffroy P. A., Samalin L., Lorca P. J. Affect. Disord. 2016;204;32-39.
20. Gonzalez R. J. Clin. Psychiatry. 2014;75:323-333.
21. Iwahana E., Akiyama M., Miyakawa K. Eur. J. Neurosci. 2004;19:2281-2287.
22. Jope R. S., Roh M. S. Curr. Drug Targets. 2006;7:1421-1434.
23. Kaladchibachi S. A., Doble B., Anthonopoulos N. J. Circadian. Rhythms. 2007;5:3-10.
24. Kinoshita C., Miyazaki K., Ishida N. Neuroreport. 2012;23:98-102.
25. Luca A., Calandia C., Luca M. Oxid. Med. Cell Longev. 2016;30:547-550.
26. McClung C. A., Cold. Spring Harb. Symp. Quant. Biol. 2007;72:637-644.
27. Milhiet V., Boudebesse C., Bellivier F. Front. Biosci. 2014;6:120-137.
28. Moreira J., Geoffroy P. A. Chronobiol. Int. 2016;33:351-373.
29. Murray G., Harvey A. Bipol. Disord. 2010;12:459-472.
30. Nierenberg A. A. Psychother. Psychosom. 2009;78:391-393.
31. Reiter R. J., Calvo J. R., Karbownik K. H. Ann. N.Y. Acad. Sci. 2000;917:376-386.
32. Seggie J., Westiuk E. S, Grota L. Prog. Neuropharmacol. Biol. Psychiatry. 1987;11:325-334.
33. Souza L. G., Wilhelm E. A., Bortrolatto C. F. Behav. Brain Res. 2014;271:316-324.
34. Valvassori S. S., Dal-Pint G. C., Resende W. R. Neuropharmacology. 2016;24:282-290.
35. Valvassori S. S., Rezin G. T., Ferreira C. L. J. Psychiatry Res. 2010;44:903-909.

Keywords: lithium, bipolar affective disorder, melatonin


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy